While they could rescue the DCM phenotype by individually targeting each mutation, PE offers the advantage of providing one single molecular therapy for two genetically heterogeneous patient cohorts with either one of the two RBM20 mutations. Here, RBM20 is linked to familial dilated cardiomyopathy.